Terminated PHASE2 INTERVENTIONAL 2-arm NCT01122511

Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

Sponsor: Allergan

Conditions Age-Related Maculopathy Subfoveal Choroidal Neovascularization

Interventions 700 ug dexamethasone ranibizumab sham

Updated 9 times since 2017 Last updated: Aug 1, 2012 Started: Aug 31, 2010 Primary completion: May 31, 2011 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated early due to difficulties with patient recruitment.

Other terminated trials from Allergan

See all terminations from Allergan

A PHASE2 clinical study on Age-Related Maculopathy and Subfoveal Choroidal Neovascularization, this trial is terminated or withdrawn. The trial is conducted by Allergan and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2
Dec 2021 — Dec 2022 [monthly]

Terminated PHASE2

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Abilene, United States
• Fort Myers, United States